- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09:30 | Magle Chemoswed Holding AB: Magle Group Publishes Information Document in Connection with Upcoming Rights Issue | 103 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH... ► Artikel lesen | |
| Mo | XFRA CAPITAL ADJUSTMENT INFORMATION - 13.04.2026 | 67 | Xetra Newsboard | Das Instrument LUR SE0015192075 LUXBRIGHT AB EQUITY wird ex Kapitalmassnahme gehandelt am 13.04.2026 The instrument LUR SE0015192075 LUXBRIGHT AB EQUITY is traded ex capital adjustment on 13.04.2026Das... ► Artikel lesen | |
| Fr | Magle Chemoswed Holding AB: Bulletin from the extraordinary general meeting in Magle Chemoswed Holding AB (publ) | 114 | GlobeNewswire (Europe) | Magle Chemoswed Holding AB (publ), reg. no. 556913-4710 (the "Company"), today, on 10 April 2026, held an Extraordinary General Meeting (the "EGM") at the Company's premises at Agneslundsvägen 20B in... ► Artikel lesen | |
| MAGLE CHEMOSWED Aktie jetzt für 0€ handeln | |||||
| 27.03. | Magle Chemoswed Holding AB: Magle Chemoswed Holding Reports Financial Results For Fourth Quarter 2025 | 132 | GlobeNewswire (Europe) | Magle Group's Q4 report highlights restructuring measures, portfolio clean-up and a focus on improving profitability in a challenging financial environment.
Q4 2025 KEY INDICATORSNet Sales amounted... ► Artikel lesen | |
| 25.03. | Magle Chemoswed Holding AB: Magle Group's Board Of Directors Has Resolved On A Rights Issue Of Approx Sek 40 Million And Agreed A Revised Financing Package | 110 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH... ► Artikel lesen | |
| 18.02. | Magle Chemoswed Holding AB: Magle Group Issues Profit Warning Ahead of Q4 and Full-Year 2025 Results | 136 | GlobeNewswire (Europe) | Magle Group today issues a profit warning in advance of the publication of its Q4 2025 Interim Report and Full-Year 2025 Results, now scheduled for release on March 27, 2026.
This follows the Group's... ► Artikel lesen | |
| 29.01. | Magle Chemoswed Holding AB: Magle Group Announces Strategic Refocus to Strengthen Profitability and Operational Discipline | 171 | GlobeNewswire (Europe) | Magle Group today announces a strategic direction focused on strengthening profitability, operational discipline, and long-term value creation. The Group will prioritise its most established revenue-generating... ► Artikel lesen | |
| 21.01. | Magle Chemoswed Holding AB: Magle Group Announces Planned Transition in Chief Operating Officer Role | 134 | GlobeNewswire (Europe) | Magle Group today announces that Fredrik Andersson, Chief Operating Officer, will step down from his position during the coming months, as part of a planned leadership transition. This decision has... ► Artikel lesen | |
| 01.12.25 | Magle Chemoswed Holding AB: Magle Group Enters Strategic Distribution Agreement with Rifa Pharma for SmartPAN and SmartGEL in India. | 168 | GlobeNewswire (Europe) | Magle Group is pleased to announce that it has entered into an exclusive distribution agreement with Rifa Pharma for the Indian market, covering both SmartPAN® and SmartGEL®.
This partnership represents... ► Artikel lesen | |
| 27.11.25 | Magle Chemoswed Holding AB: Magle Chemoswed Holding Announces Chairman Transition | 162 | GlobeNewswire (Europe) | As of today, Hans Henrik Lidgard steps down as Chairman of the Board for health reasons and will remain on the Board. In accordance with the procedural rules of the Board of the Company, Vice-Chairman... ► Artikel lesen | |
| 17.11.25 | Magle Chemoswed Holding AB: Magle Group Completes European Medical Device Filing for the Use of EmboCept S in Genicular Artery Embolisation | 297 | GlobeNewswire (Europe) | Magle Group today announces that it has successfully completed its European medical device filing to extend the clinical use of EmboCept® S, the company's proprietary degradable starch microsphere (DSM)... ► Artikel lesen | |
| 14.11.25 | Magle Chemoswed Holding AB: Magle Chemoswed Holding Reports Financial Results For Third Quarter 2025 | 191 | GlobeNewswire (Europe) | Magle Group announces its Q3 2025 results, marked by clear progress across key areas of the business.
Q3 2025 KEY INDICATORSNet Sales amounted to 71.5 MSEK (64.6)EBITDA equaled 33.4 MSEK (26.5)Operating... ► Artikel lesen | |
| 22.10.25 | Magle Chemoswed Holding AB: Magle Biopolymers receives 2026 order showing a material increase in demand for one of its proprietary dextran derivatives | 256 | GlobeNewswire (Europe) | Magle Chemoswed Holding AB (publ) ("Magle Group") today announces that its subsidiary, Magle Biopolymers AB, has received an order for 2026 from a customer, representing a material increase in demand... ► Artikel lesen | |
| 20.10.25 | Magle Chemoswed Holding AB: Magle Group announces positive clinical evidence review of EmboCept S for Genicular Artery Embolisation (GAE); regulatory filing in Europe now in preparation | 228 | GlobeNewswire (Europe) | Magle Group today announces that its review of available clinical evidence for the use of EmboCept® S in Genicular Artery Embolisation (GAE) for symptomatic knee osteoarthritis demonstrates excellent... ► Artikel lesen | |
| 01.08.25 | Magle Chemoswed Holding AB: Magle Chemoswed Holding Reports Financial Results For Second Quarter 2025 | 232 | GlobeNewswire (Europe) | Magle Group announces its Q2 2025 results amid short-term macroeconomic challenges, highlighting underlying strategic progress despite a temporary setback in financial performance. The quarter was impacted... ► Artikel lesen | |
| 29.07.25 | Magle Chemoswed Holding AB: Magle Group's financial results for the second quarter anticipated to fall short of market expectations. | 216 | GlobeNewswire (Europe) | Magle Chemoswed Holding AB (publ) ("Magle Group") today announces that the company's financial performance in the second quarter of 2025 is likely to fall short of market estimates. The deviation is... ► Artikel lesen | |
| 05.06.25 | Magle Chemoswed Holding AB: The acquisition of all shares in Saving Chlora AB has been completed | 305 | GlobeNewswire (Europe) | On 24 April 2025, Magle Chemoswed Holding AB ("Magle Group" or the "Company") announced that the Company had signed a share purchase agreement regarding the acquisition of all shares in Saving Chlora... ► Artikel lesen | |
| 26.05.25 | Magle Chemoswed Holding AB: Bulletin from Annual General Meeting in Magle Chemoswed Holding AB (publ) held on the 26th of May 2025 | 246 | GlobeNewswire (Europe) | Today, on the 26th of May 2025 the annual general meeting was held in Magle Chemoswed Holding AB (publ).
A summary of the adopted resolutions follows below:Adoption of the Income Statement and Balance... ► Artikel lesen | |
| 22.05.25 | Magle Chemoswed Holding AB: Magle Chemoswed Holding Reports Financial Results For First Quarter 2025 | 342 | GlobeNewswire (Europe) | Magle Group's Q1 report highlights a continuation of steady revenue growth in DSM and CDMO, with increased clinical partnerships. Planned strategic investments in 2025 are set to enhance the company's... ► Artikel lesen | |
| 24.04.25 | Magle Chemoswed Holding AB: Magle Group Announces Acquisition of Saving Chlora AB | 410 | GlobeNewswire (Europe) | Magle Chemoswed Holding AB ("Magle Group" or the "Company") has today, on 24 April 2025, signed a share purchase agreement regarding the acquisition of all shares in Saving Chlora AB ("Saving Chlora")... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 119,18 | +0,83 % | BREAKING: Für bis zu 5 Milliarden Dollar! Gilead kauft Biotech-Firma aus München | Das Übernahme-Karussell im Biotech-Sektor dreht sich gefühlt von Woche zu Woche immer schneller. Erst am Ostermontag hat Neurocrine Biosciences die milliardenschwere Übernahme von Soleno Therapeutics... ► Artikel lesen | |
| SNDL | 1,173 | +0,51 % | SNDL Inc.: SNDL Announces Leadership Transition for Cannabis Segment | EDMONTON, Alberta, March 30, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ: SNDL, CSE: SNDL) ("SNDL" or the "Company") announced today that Tyler Robson, President of Cannabis, has left the Company in... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 69,58 | +1,73 % | Nektar Therapeutics: Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting | Rezpegaldesleukin demonstrates statistically significant improvement in mean percent EASI improvement across both moderate and severe atopic dermatitis patients
Rezpegaldesleukin... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 11,650 | +5,57 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and ... | Intranasal oxytocin blocks the release of calcitonin gene-related peptide (CGRP) in animal models and is the core technology of TNX-1900 for craniofacial pain conditions, including migraine and trigeminal... ► Artikel lesen | |
| HIGH TIDE | 1,984 | 0,00 % | High Tide wird auf mehreren bedeutenden internationalen Cannabis- und Investorenkonferenzen vertreten sein | CALGARY, AB, 13. April 2026 / IRW-Press / High Tide Inc. ("High Tide" oder das "Unternehmen") (Nasdaq: HITI) (TSXV: HITI) (FWB: 2LYA), ein erfolgreiches und auf
den Einzelhandel ausgerichtetes... ► Artikel lesen | |
| BACHEM | 80,40 | +5,17 % | Bachem FY25 Earnings Rise; Proposes Dividend Increase; Guides FY26 | WASHINGTON (dpa-AFX) - Bachem Holding AG (BCHMY, BCHMF), a Swiss biotechnology company, on Thursday reported higher full-year 2025 net income compared with the previous year, proposed a dividend... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 2,982 | +1,55 % | Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates | Achieve also Announces Partnership with U.S.-based Adare Pharma Solutions for Cytisinicline Manufacturing Conference Call Scheduled for 8:30 AM EDT Today, March 24, 2026 SEATTLE and VANCOUVER, British... ► Artikel lesen | |
| COSMO PHARMACEUTICALS | 103,40 | +3,19 % | Cosmo Pharmaceuticals N.V.: Voting Results of Cosmo's 2026 AGM | Dublin, Ireland--(Newsfile Corp. - April 10, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") announced that its shareholders approved all voting items at today's Ordinary... ► Artikel lesen | |
| ADDEX THERAPEUTICS | 0,047 | +2,20 % | Addex Therapeutics: Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment | Data published in Molecular Psychiatry
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, February 3, 2026
-
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage... ► Artikel lesen | |
| WAVE LIFE SCIENCES | 6,150 | 0,00 % | Wave Life Sciences Ltd.: Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following ... | At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral fat (-14%; p WVE-007 led to greater improvement in... ► Artikel lesen | |
| CANNABIST COMPANY | 0,025 | -100,00 % | Cannabist Co Holdings Inc. - 8-K, Current Report | ||
| VERTICAL AEROSPACE | 2,204 | +5,96 % | Cantor Fitzgerald reiterates Vertical Aerospace stock Overweight rating | ||
| TERRASCEND | 0,500 | -5,66 % | TerrAscend Reports Fourth Quarter and Full Year 2025 Financial Results | Net Revenue of $66.1 million for Q4 2025 and $260.6 Million for FY 2025 Gross Profit Margin of 52.1% for Q4 2025 and 52.3% for FY 2025 from continuing operations Q4 2025 Net Cash provided from continuing... ► Artikel lesen | |
| MINDWALK | 0,970 | +4,30 % | Highflyer der Zukunft - "Must Have" für ihr Biotech-Depot?! | ||
| CIPHER PHARMACEUTICALS | 11,000 | 0,00 % | Cipher Pharmaceuticals übertrifft Gewinnerwartungen, verfehlt aber Umsatzziel |
Das Unternehmen MAGLE CHEMOSWED HOLDING AB kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,364 Euro und damit +1,68 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAGLE CHEMOSWED HOLDING AB finden Sie auf Wallstreet Online.